All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Case study: Spesolimab for the treatment of GPP flare
By Ella Dixon
Generalized pustular psoriasis (GPP) results in acute, widespread onset of erythematous plaques with pustules, and can be difficult-to-treat.1 Spesolimab, an interleukin-36 inhibitor, has previously shown efficacy in treating GPP flares in the Effisayil-1 trial.1 Here, we summarize a case study by Brigenti et al.1 published in Sage Open Medical Case Reports on the treatment of GPP flare with spesolimab.
Patient history1
-
A 48-year-old patient, with a long history of psoriasis experienced a GPP flare after previously having stable disease, controlled by secukinumab for 6 years (Figure 1).
Figure 1. Patient history*
GPP, generalized pustular psoriasis.
*Data from Brigenti, et al.1 Created with BioRender.com.
Flare and treatment1
-
In October 2022, the patient experienced a severe GPP flare (Figure 2). In addition, she experienced fatigue, malaise, fever, and agitation.
-
To treat the flare, two doses of spesolimab 900 mg were administered intravenously (Figure 3). After 5 months of follow-up, the patient achieved complete clinical remission.
Figure 2. Characteristics of GPP flare*
DLQI, Dermatology Life Quality Index; GPPASI, Generalized Pustular Psoriasis Area and Severity Index; GPPGA, Generalized Pustular Psoriasis Physician’s Global Assessment.
*Data from Brigenti, et al.1 Created with BioRender.com.
Figure 3. Treatment timeline*
GPP, generalized pustular psoriasis.
*Data from Brigenti, et al.1 Created with BioRender.com.
After GPP reoccurrence at 5 months, treatment with secukinumab 300 mg led to clinical remission (measured at 8 months)
-
Generalized Pustular Psoriasis Physician’s Global Assessment score: 0
-
Generalized Pustular Psoriasis Area and Severity Index score: 0
-
Dermatology Life Quality Index: 1
|
Key learnings |
|
- Brigenti N, Gisondi P, Bellinato F, et al. Generalized pustular psoriasis successfully treated with spesolimab: A case report. SAGE Open Med Case Rep. 2024;12:2050313X241235451. DOI: 10.1177/2050313X241235451
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox